Abstract
Traumatic brain injury (TBI) is an injury to the brain caused by an external mechanical force, affecting millions of people worldwide. The disease course and prognosis are often unpredictable, and it can be challenging to determine an early diagnosis in case of mild injury as well as to accurately phenotype the injury. There is currently no cure for TBI—drugs having failed repeatedly in clinical trials—but an intense effort has been put to identify effective neuroprotective treatment. The detection of novel biomarkers, to understand more of the disease mechanism, facilitates early diagnosis, predicts disease progression, and develops molecularly targeted therapies that would be of high clinical interest. Over the last decade, there has been an increasing effort and initiative toward finding TBI-specific biomarker candidates. One promising strategy has been to use state-of-the-art neuroproteomics approaches to assess clinical biofluids and compare the cerebrospinal fluid (CSF) and blood proteome between TBI and control patients or between different subgroups of TBI. In this chapter, we summarize and discuss the status of biofluid proteomics in TBI, with a particular focus on the latest findings.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Maas AI, Stocchetti N, Bullock R (2008) Moderate and severe traumatic brain injury in adults. Lancet Neurol 7:728–741
Roozenbeek B, Maas AI, Menon DK (2013) Changing patterns in the epidemiology of traumatic brain injury. Nat Rev Neurol 9:231–236
Finfer SR, Cohen J (2001) Severe traumatic brain injury. Resuscitation 48:77–90
Kobeissy F, Mondello S, Tumer N, Toklu HZ, Whidden MA, Kirichenko N, Zhang Z, Prima V, Yassin W, Anagli J, Chandra N, Svetlov S, Wang KK (2013) Assessing neuro-systemic & behavioral components in the pathophysiology of blast-related brain injury. Front Neurol 4:186
Wagner AK, Zitelli KT (2013) A Rehabilomics focused perspective on molecular mechanisms underlying neurological injury, complications, and recovery after severe TBI. Pathophysiology 20:39–48
Maas AI, Murray GD, Roozenbeek B, Lingsma HF, Butcher I, McHugh GS, Weir J, Lu J, Steyerberg EW, International Mission on Prognosis Analysis of Clinical Trials in Traumatic Brain Injury Study, G (2013) Advancing care for traumatic brain injury: findings from the IMPACT studies and perspectives on future research. Lancet Neurol 12:1200–1210
Wright DW, Yeatts SD, Silbergleit R, Palesch YY, Hertzberg VS, Frankel M, Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM, Manley GT, Merck LH, Janis LS, Barsan WG, Investigators N (2014) Very early administration of progesterone for acute traumatic brain injury. N Engl J Med 371:2457–2466
Mondello S, Muller U, Jeromin A, Streeter J, Hayes RL, Wang KK (2011) Blood-based diagnostics of traumatic brain injuries. Expert Rev Mol Diagn 11:65–78
Mondello S, Hayes RL (2015) Biomarkers. Handb Clin Neurol 127:245–265
Guingab-Cagmat JD, Newsom K, Vakulenko A, Cagmat EB, Kobeissy FH, Zoltewicz S, Wang KK, Anagli J (2012) In vitro MS-based proteomic analysis and absolute quantification of neuronal-glial injury biomarkers in cell culture system. Electrophoresis 33:3786–3797
Mann M, Kulak NA, Nagaraj N, Cox J (2013) The coming age of complete, accurate, and ubiquitous proteomes. Mol Cell 49:583–590
Ottens AK, Kobeissy FH, Golden EC, Zhang Z, Haskins WE, Chen SS, Hayes RL, Wang KK, Denslow ND (2006) Neuroproteomics in neurotrauma. Mass Spectrom Rev 25:380–408
Kobeissy FH, Ottens AK, Zhang Z, Liu MC, Denslow ND, Dave JR, Tortella FC, Hayes RL, Wang KK (2006) Novel differential neuroproteomics analysis of traumatic brain injury in rats. Mol Cell Proteomics 5:1887–1898
Petzold A (2007) CSF biomarkers for improved prognostic accuracy in acute CNS disease. Neurol Res 29:691–708
Zetterberg H, Smith DH, Blennow K (2013) Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol 9:201–210
Shlosberg D, Benifla M, Kaufer D, Friedman A (2010) Blood-brain barrier breakdown as a therapeutic target in traumatic brain injury. Nat Rev Neurol 6:393–403
Siman R, McIntosh TK, Soltesz KM, Chen Z, Neumar RW, Roberts VL (2004) Proteins released from degenerating neurons are surrogate markers for acute brain damage. Neurobiol Dis 16:311–320
Evans RW (1998) Complications of lumbar puncture. Neurol Clin 16:83–105
Elliott MH, Smith DS, Parker CE, Borchers C (2009) Current trends in quantitative proteomics. J Mass Spectrom 44:1637–1660
Anderson NL, Anderson NG (2002) The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 1:845–867
Guerrier L, Lomas L, Boschetti E (2005) A simplified monobuffer multidimensional chromatography for high-throughput proteome fractionation. J Chromatogr A 1073:25–33
Pan S, Zhu D, Quinn JF, Peskind ER, Montine TJ, Lin B, Goodlett DR, Taylor G, Eng J, Zhang J (2007) A combined dataset of human cerebrospinal fluid proteins identified by multi-dimensional chromatography and tandem mass spectrometry. Proteomics 7:469–473
Koutroukides TA, Guest PC, Leweke FM, Bailey DM, Rahmoune H, Bahn S, Martins-de-Souza D (2011) Characterization of the human serum depletome by label-free shotgun proteomics. J Sep Sci 34:1621–1626
Haqqani AS, Hutchison JS, Ward R, Stanimirovic DB (2007) Biomarkers and diagnosis; protein biomarkers in serum of pediatric patients with severe traumatic brain injury identified by ICAT-LC-MS/MS. J Neurotrauma 24:54–74
Lizhnyak PN, Yohannes H, Ottens AK (2015) Neuroproteome dynamics in modeled brain injury: a systems neurobiology perspective. In: Kobeissy FH (ed) Brain neurotrauma: molecular, neuropsychological, and rehabilitation aspects. CRC Press/Taylor & Francis, Boca Raton, FL, pp 371–378
Wolahan SM, Hirt D, Glenn TC (2015) Translational metabolomics of head injury: exploring dysfunctional cerebral metabolism with ex vivo NMR spectroscopy-based metabolite quantification. In: Kobeissy FH (ed) Brain neurotrauma: molecular, neuropsychological, and rehabilitation aspects. CRC Press/Taylor & Francis, Boca Raton, FL, pp 371–378
Marangos PJ, Schmechel DE (1987) Neuron specific enolase, a clinically useful marker for neurons and neuroendocrine cells. Annu Rev Neurosci 10:269–295
Vos PE, Lamers KJ, Hendriks JC, van Haaren M, Beems T, Zimmerman C, van Geel W, de Reus H, Biert J, Verbeek MM (2004) Glial and neuronal proteins in serum predict outcome after severe traumatic brain injury. Neurology 62:1303–1310
Meric E, Gunduz A, Turedi S, Cakir E, Yandi M (2010) The prognostic value of neuron-specific enolase in head trauma patients. J Emerg Med 38:297–301
Berger RP (2006) The use of serum biomarkers to predict outcome after traumatic brain injury in adults and children. J Head Trauma Rehabil 21:315–333
Berger RP, Adelson PD, Richichi R, Kochanek PM (2006) Serum biomarkers after traumatic and hypoxemic brain injuries: insight into the biochemical response of the pediatric brain to inflicted brain injury. Dev Neurosci 28:327–335
Zetterberg H, Tanriverdi F, Unluhizarci K, Selcuklu A, Kelestimur F, Blennow K (2009) Sustained release of neuron-specific enolase to serum in amateur boxers. Brain Inj 23:723–726
Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, Edman A, Popa C, Rasulzada A, Wahlund LO, Mehta PD, Rosengren L, Blennow K, Wallin A (2006) Neurochemical aftermath of amateur boxing. Arch Neurol 63:1277–1280
Berger RP, Pierce MC, Wisniewski SR, Adelson PD, Clark RS, Ruppel RA, Kochanek PM (2002) Neuron-specific enolase and S100B in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatrics 109:E31
Pelinka LE, Hertz H, Mauritz W, Harada N, Jafarmadar M, Albrecht M, Redl H, Bahrami S (2005) Nonspecific increase of systemic neuron-specific enolase after trauma: clinical and experimental findings. Shock 24:119–123
Day IN, Thompson RJ (2010) UCHL1 (PGP 9.5): neuronal biomarker and ubiquitin system protein. Prog Neurobiol 90:327–362
Gong B, Leznik E (2007) The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect 20:365–370
Tongaonkar P, Chen L, Lambertson D, Ko B, Madura K (2000) Evidence for an interaction between ubiquitin-conjugating enzymes and the 26S proteasome. Mol Cell Biol 20:4691–4698
Liu MC, Akinyi L, Scharf D, Mo J, Larner SF, Muller U, Oli MW, Zheng W, Kobeissy F, Papa L, Lu XC, Dave JR, Tortella FC, Hayes RL, Wang KK (2010) Ubiquitin C-terminal hydrolase-L1 as a biomarker for ischemic and traumatic brain injury in rats. Eur J Neurosci 31:722–732
Blyth BJ, Farahvar A, He H, Nayak A, Yang C, Shaw G, Bazarian JJ (2011) Elevated serum ubiquitin carboxy-terminal hydrolase L1 is associated with abnormal blood-brain barrier function after traumatic brain injury. J Neurotrauma 28:2453–2462
Brophy GM, Mondello S, Papa L, Robicsek SA, Gabrielli A, Tepas J 3rd, Buki A, Robertson C, Tortella FC, Hayes RL, Wang KK (2011) Biokinetic analysis of ubiquitin C-terminal hydrolase-L1 (UCH-L1) in severe traumatic brain injury patient biofluids. J Neurotrauma 28:861–870
Czeiter E, Mondello S, Kovacs N, Sandor J, Gabrielli A, Schmid K, Tortella F, Wang KK, Hayes RL, Barzo P, Ezer E, Doczi T, Buki A (2012) Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. J Neurotrauma 29:1770–1778
Mondello S, Linnet A, Buki A, Robicsek S, Gabrielli A, Tepas J, Papa L, Brophy GM, Tortella F, Hayes RL, Wang KK (2012) Clinical utility of serum levels of ubiquitin C-terminal hydrolase as a biomarker for severe traumatic brain injury. Neurosurgery 70:666–675
Papa L, Akinyi L, Liu MC, Pineda JA, Tepas JJ 3rd, Oli MW, Zheng W, Robinson G, Robicsek SA, Gabrielli A, Heaton SC, Hannay HJ, Demery JA, Brophy GM, Layon J, Robertson CS, Hayes RL, Wang KK (2009) Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury. Crit Care Med 38:138–144
Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, Brophy GM, Demery JA, Dixit NK, Ferguson I, Liu MC, Mo J, Akinyi L, Schmid K, Mondello S, Robertson CS, Tortella FC, Hayes RL, Wang KK (2011) Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 59:471–483
Papa L, Lewis LM, Silvestri S, Falk JL, Giordano P, Brophy GM, Demery JA, Liu MC, Mo J, Akinyi L, Mondello S, Schmid K, Robertson CS, Tortella FC, Hayes RL, Wang KK (2012) Serum levels of ubiquitin C-terminal hydrolase distinguish mild traumatic brain injury from trauma controls and are elevated in mild and moderate traumatic brain injury patients with intracranial lesions and neurosurgical intervention. J Trauma Acute Care Surg 72:1335–1344
Mondello S, Kobeissy F, Vestri A, Hayes RL, Kochanek PM, Berger RP (2016) Serum concentrations of ubiquitin C-terminal hydrolase-L1 and glial fibrillary acidic protein after pediatric traumatic brain injury. Sci Rep 6:28203
Mondello S, Papa L, Buki A, Bullock MR, Czeiter E, Tortella FC, Wang KK, Hayes RL (2011) Neuronal and glial markers are differently associated with computed tomography findings and outcome in patients with severe traumatic brain injury: a case control study. Crit Care 15:R156
Papa L, Ramia MM, Kelly JM, Burks SS, Pawlowicz A, Berger RP (2013) Systematic review of clinical research on biomarkers for pediatric traumatic brain injury. J Neurotrauma 30:324–338
Welch RD, Ayaz SI, Lewis LM, Unden J, Chen JY, Mika VH, Saville B, Tyndall JA, Nash M, Buki A, Barzo P, Hack D, Tortella FC, Schmid K, Hayes RL, Vossough A, Sweriduk ST, Bazarian JJ (2016) Ability of serum glial fibrillary acidic protein, ubiquitin C-terminal hydrolase-L1, and S100B to differentiate normal and abnormal head computed tomography findings in patients with suspected mild or moderate traumatic brain injury. J Neurotrauma 33:203–214
Liu Q, Xie F, Siedlak SL, Nunomura A, Honda K, Moreira PI, Zhua X, Smith MA, Perry G (2004) Neurofilament proteins in neurodegenerative diseases. Cell Mol Life Sci 61:3057–3075
Friede RL, Samorajski T (1970) Axon caliber related to neurofilaments and microtubules in sciatic nerve fibers of rats and mice. Anat Rec 167:379–387
Povlishock JT, Marmarou A, McIntosh T, Trojanowski JQ, Moroi J (1997) Impact acceleration injury in the rat: evidence for focal axolemmal change and related neurofilament sidearm alteration. J Neuropathol Exp Neurol 56:347–359
Bacioglu M, Maia LF, Preische O, Schelle J, Apel A, Kaeser SA, Schweighauser M, Eninger T, Lambert M, Pilotto A, Shimshek DR, Neumann U, Kahle PJ, Staufenbiel M, Neumann M, Maetzler W, Kuhle J, Jucker M (2016) Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91:494–496
Ljungqvist JC, Zetterberg H, Mitsis M, Blennow K, Skoglund TS (2016) Serum neurofilament light protein as a marker for diffuse axonal injury—results from a case series study. J Neurotrauma. [Epub ahead of print]
Al Nimer F, Thelin E, Nystrom H, Dring AM, Svenningsson A, Piehl F, Nelson DW, Bellander BM (2015) Comparative assessment of the prognostic value of biomarkers in traumatic brain injury reveals an independent role for serum levels of neurofilament light. PLoS One 10:e0132177
Anderson KJ, Scheff SW, Miller KM, Roberts KN, Gilmer LK, Yang C, Shaw G (2008) The phosphorylated axonal form of the neurofilament subunit NF-H (pNF-H) as a blood biomarker of traumatic brain injury. J Neurotrauma 25:1079–1085
Shaw G, Yang C, Ellis R, Anderson K, Parker Mickle J, Scheff S, Pike B, Anderson DK, Howland DR (2005) Hyperphosphorylated neurofilament NF-H is a serum biomarker of axonal injury. Biochem Biophys Res Commun 336:1268–1277
Gatson JW, Barillas J, Hynan LS, Diaz-Arrastia R, Wolf SE, Minei JP (2014) Detection of neurofilament-H in serum as a diagnostic tool to predict injury severity in patients who have suffered mild traumatic brain injury. J Neurosurg 121:1232–1238
Rostami E, Davidsson J, Ng KC, Lu J, Gyorgy A, Walker J, Wingo D, Plantman S, Bellander BM, Agoston DV, Risling M (2012) A model for mild traumatic brain injury that induces limited transient memory impairment and increased levels of axon related serum biomarkers. Front Neurol 3:115
Zurek J, Fedora M (2012) The usefulness of S100B, NSE, GFAP, NF-H, secretagogin and Hsp70 as a predictive biomarker of outcome in children with traumatic brain injury. Acta Neurochir 154:93–103. discussion 103
Zurek J, Bartlova L, Fedora M (2011) Hyperphosphorylated neurofilament NF-H as a predictor of mortality after brain injury in children. Brain Inj 25:221–226
Trojanowski JQ, Schuck T, Schmidt ML, Lee VM (1989) Distribution of tau proteins in the normal human central and peripheral nervous system. J Histochem Cytochem 37:209–215
Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70:410–426
Ost M, Nylen K, Csajbok L, Ohrfelt AO, Tullberg M, Wikkelso C, Nellgard P, Rosengren L, Blennow K, Nellgard B (2006) Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67:1600–1604
Franz G, Beer R, Kampfl A, Engelhardt K, Schmutzhard E, Ulmer H, Deisenhammer F (2003) Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury. Neurology 60:1457–1461
Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J (2012) CSF-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS One 7:e33606
Bulut M, Koksal O, Dogan S, Bolca N, Ozguc H, Korfali E, Ilcol YO, Parklak M (2006) Tau protein as a serum marker of brain damage in mild traumatic brain injury: preliminary results. Adv Ther 23:12–22
Neselius S, Zetterberg H, Blennow K, Randall J, Wilson D, Marcusson J, Brisby H (2013) Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma. Brain Inj 27:425–433
Dekosky ST, Blennow K, Ikonomovic MD, Gandy S (2013) Acute and chronic traumatic encephalopathies: pathogenesis and biomarkers. Nat Rev Neurol 9:192–200
Bazarian JJ, Zemlan FP, Mookerjee S, Stigbrand T (2006) Serum S-100B and cleaved-tau are poor predictors of long-term outcome after mild traumatic brain injury. Brain Inj 20:759–765
Kavalci C, Pekdemir M, Durukan P, Ilhan N, Yildiz M, Serhatlioglu S, Seckin D (2007) The value of serum tau protein for the diagnosis of intracranial injury in minor head trauma. Am J Emerg Med 25:391–395
Riederer BM, Zagon IS, Goodman SR (1986) Brain spectrin(240/235) and brain spectrin(240/235E): two distinct spectrin subtypes with different locations within mammalian neural cells. J Cell Biol 102:2088–2097
Zhang Z, Larner SF, Liu MC, Zheng W, Hayes RL, Wang KK (2009) Multiple alphaII-spectrin breakdown products distinguish calpain and caspase dominated necrotic and apoptotic cell death pathways. Apoptosis 14:1289–1298
Mondello S, Robicsek SA, Gabrielli A, Brophy GM, Papa L, Tepas J, Robertson C, Buki A, Scharf D, Jixiang M, Akinyi L, Muller U, Wang KK, Hayes RL (2010) alphaII-spectrin breakdown products (SBDPs): diagnosis and outcome in severe traumatic brain injury patients. J Neurotrauma 27:1203–1213
Xiong H, Liang WL, Wu XR (2000) Pathophysiological alterations in cultured astrocytes exposed to hypoxia/reoxygenation. Sheng Li Ke Xue Jin Zhan 31:217–221
Goncalves CA, Leite MC, Nardin P (2008) Biological and methodological features of the measurement of S100B, a putative marker of brain injury. Clin Biochem 41:755–763
Donato R (2001) S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33:637–668
Jonsson H, Johnsson P, Hoglund P, Alling C, Blomquist S (2000) Elimination of S100B and renal function after cardiac surgery. J Cardiothorac Vasc Anesth 14:698–701
Raabe A, Menon DK, Gupta S, Czosnyka M, Pickard JD (1998) Jugular venous and arterial concentrations of serum S-100B protein in patients with severe head injury: a pilot study. J Neurol Neurosurg Psychiatry 65:930–932
Romner B, Ingebrigtsen T, Kongstad P, Borgesen SE (2000) Traumatic brain damage: serum S-100 protein measurements related to neuroradiological findings. J Neurotrauma 17:641–647
Woertgen C, Rothoerl RD, Metz C, Brawanski A (1999) Comparison of clinical, radiologic, and serum marker as prognostic factors after severe head injury. J Trauma 47:1126–1130
Raabe A, Grolms C, Keller M, Dohnert J, Sorge O, Seifert V (1998) Correlation of computed tomography findings and serum brain damage markers following severe head injury. Acta Neurochir 140:787–791. discussion 791–782
Raabe A, Grolms C, Sorge O, Zimmermann M, Seifert V (1999) Serum S-100B protein in severe head injury. Neurosurgery 45:477–483
Rothoerl RD, Woertgen C, Holzschuh M, Metz C, Brawanski A (1998) S-100 serum levels after minor and major head injury. J Trauma 45:765–767
Herrmann M, Curio N, Jost S, Wunderlich MT, Synowitz H, Wallesch CW (1999) Protein S-100B and neuron specific enolase as early neurobiochemical markers of the severity of traumatic brain injury. Restor Neurol Neurosci 14:109–114
McKeating EG, Andrews PJ, Mascia L (1998) Relationship of neuron specific enolase and protein S-100 concentrations in systemic and jugular venous serum to injury severity and outcome after traumatic brain injury. Acta Neurochir Suppl 71:117–119
Pelinka LE, Kroepfl A, Leixnering M, Buchinger W, Raabe A, Redl H (2004) GFAP versus S100B in serum after traumatic brain injury: relationship to brain damage and outcome. J Neurotrauma 21:1553–1561
Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M (2004) Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. J Trauma 56:1229–1234. discussion 1234
Vos PE, Jacobs B, Andriessen TM, Lamers KJ, Borm GF, Beems T, Edwards M, Rosmalen CF, Vissers JL (2010) GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study. Neurology 75:1786–1793
Woertgen C, Rothoerl RD, Holzschuh M, Metz C, Brawanski A (1997) Comparison of serial S-100 and NSE serum measurements after severe head injury. Acta Neurochir 139:1161–1164. discussion 1165
Unden J, Astrand R, Waterloo K, Ingebrigtsen T, Bellner J, Reinstrup P, Andsberg G, Romner B (2007) Clinical significance of serum S100B levels in neurointensive care. Neurocrit Care 6:94–99
Kovesdi E, Luckl J, Bukovics P, Farkas O, Pal J, Czeiter E, Szellar D, Doczi T, Komoly S, Buki A (2010) Update on protein biomarkers in traumatic brain injury with emphasis on clinical use in adults and pediatrics. Acta Neurochir 152:1–17
Unden J, Romner B (2010) Can low serum levels of S100B predict normal CT findings after minor head injury in adults?: an evidence-based review and meta-analysis. J Head Trauma Rehabil 25:228–240
Unden J, Ingebrigtsen T, Romner B, Scandinavian Neurotrauma C (2013) Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults: an evidence and consensus-based update. BMC Med 11:50
Mussack T, Kirchhoff C, Buhmann S, Biberthaler P, Ladurner R, Gippner-Steppert C, Mutschler W, Jochum M (2006) Significance of Elecsys S100 immunoassay for real-time assessment of traumatic brain damage in multiple trauma patients. Clin Chem Lab Med 44:1140–1145
Romner B, Ingebrigtsen T (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 49:1490. author reply 1492–1493
Rothoerl RD, Woertgen C (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 49:1490–1491. author reply 1492–1493
Stalnacke BM, Ohlsson A, Tegner Y, Sojka P (2006) Serum concentrations of two biochemical markers of brain tissue damage S-100B and neurone specific enolase are increased in elite female soccer players after a competitive game. Br J Sports Med 40:313–316
Anderson RE, Hansson LO, Nilsson O, Dijlai-Merzoug R, Settergren G (2001) High serum S100B levels for trauma patients without head injuries. Neurosurgery 48:1255–1258. discussion 1258–1260
Lange RT, Iverson GL, Brubacher JR (2012) Clinical utility of the protein S100B to evaluate traumatic brain injury in the presence of acute alcohol intoxication. J Head Trauma Rehabil 27:123–134
Berger RP, Dulani T, Adelson PD, Leventhal JM, Richichi R, Kochanek PM (2006) Identification of inflicted traumatic brain injury in well-appearing infants using serum and cerebrospinal markers: a possible screening tool. Pediatrics 117:325–332
Piazza O, Storti MP, Cotena S, Stoppa F, Perrotta D, Esposito G, Pirozzi N, Tufano R (2007) S100B is not a reliable prognostic index in paediatric TBI. Pediatr Neurosurg 43:258–264
Eng LF, Ghirnikar RS, Lee YL (2000) Glial fibrillary acidic protein: GFAP-thirty-one years (1969–2000). Neurochem Res 25:1439–1451
Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B (1971) An acidic protein isolated from fibrous astrocytes. Brain Res 28:351–354
Schiff L, Hadker N, Weiser S, Rausch C (2012) A literature review of the feasibility of glial fibrillary acidic protein as a biomarker for stroke and traumatic brain injury. Mol Diagn Ther 16:79–92
Pelinka LE, Kroepfl A, Schmidhammer R, Krenn M, Buchinger W, Redl H, Raabe A (2004) Glial fibrillary acidic protein in serum after traumatic brain injury and multiple trauma. J Trauma 57:1006–1012
Missler U, Wiesmann M, Wittmann G, Magerkurth O, Hagenstrom H (1999) Measurement of glial fibrillary acidic protein in human blood: analytical method and preliminary clinical results. Clin Chem 45:138–141
van Geel WJ, de Reus HP, Nijzing H, Verbeek MM, Vos PE, Lamers KJ (2002) Measurement of glial fibrillary acidic protein in blood: an analytical method. Clin Chim Acta 326:151–154
O'Callaghan JP, Sriram K (2005) Glial fibrillary acidic protein and related glial proteins as biomarkers of neurotoxicity. Expert Opin Drug Saf 4:433–442
Mondello S, Jeromin A, Buki A, Bullock R, Czeiter E, Kovacs N, Barzo P, Schmid K, Tortella F, Wang KK, Hayes RL (2011) Glial neuronal ratio: a novel index for differentiating injury type in patients with severe traumatic brain injury. J Neurotrauma 29:1096–1104
Nylen K, Ost M, Csajbok LZ, Nilsson I, Blennow K, Nellgard B, Rosengren L (2006) Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci 240:85–91
Wiesmann M, Steinmeier E, Magerkurth O, Linn J, Gottmann D, Missler U (2010) Outcome prediction in traumatic brain injury: comparison of neurological status, CT findings, and blood levels of S100B and GFAP. Acta Neurol Scand 121:178–185
Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, Brophy GM, Demery JA, Dixit NK, Ferguson I, Liu MC, Mo J, Akinyi L, Schmid K, Mondello S, Robertson CS, Tortella FC, Hayes RL, Wang KK (2012) Elevated levels of serum glial fibrillary acidic protein breakdown products in mild and moderate traumatic brain injury are associated with intracranial lesions and neurosurgical intervention. Ann Emerg Med 59:471–483
Metting Z, Wilczak N, Rodiger LA, Schaaf JM, van der Naalt J (2012) GFAP and S100B in the acute phase of mild traumatic brain injury. Neurology 78:1428–1433
Fraser DD, Close TE, Rose KL, Ward R, Mehl M, Farrell C, Lacroix J, Creery D, Kesselman M, Stanimirovic D, Hutchison JS, Canadian Critical Care Translational Biology G (2011) Severe traumatic brain injury in children elevates glial fibrillary acidic protein in cerebrospinal fluid and serum. Pediatr Crit Care Med 12:319–324
Hayes RL, Mondello S, Wang K (2011) Glial fibrillary acidic protein: a promising biomarker in pediatric brain injury. Pediatr Crit Care Med 12:603–604
Barbarese E, Barry C, Chou CH, Goldstein DJ, Nakos GA, Hyde-DeRuyscher R, Scheld K, Carson JH (1988) Expression and localization of myelin basic protein in oligodendrocytes and transfected fibroblasts. J Neurochem 51:1737–1745
Armstrong RC, Mierzwa AJ, Sullivan GM, Sanchez MA (2016) Myelin and oligodendrocyte lineage cells in white matter pathology and plasticity after traumatic brain injury. Neuropharmacology 110(Pt B):654–659
Palfreyman JW, Thomas DG, Ratcliffe JG (1978) Radioimmunoassay of human myelin basic protein in tissue extract, cerebrospinal fluid and serum and its clinical application to patients with head injury. Clin Chim Acta 82:259–270
Thomas DG, Palfreyman JW, Ratcliffe JG (1978) Serum-myelin-basic-protein assay in diagnosis and prognosis of patients with head injury. Lancet 1:113–115
Thomas DG, Rabow L, Teasdale G (1979) Serum myelin basic protein, clinical responsiveness, and outcome of severe head injury. Acta Neurochir Suppl 28:93–95
Yan EB, Satgunaseelan L, Paul E, Bye N, Nguyen P, Agyapomaa D, Kossmann T, Rosenfeld JV, Morganti-Kossmann MC (2014) Post-traumatic hypoxia is associated with prolonged cerebral cytokine production, higher serum biomarker levels, and poor outcome in patients with severe traumatic brain injury. J Neurotrauma 31:618–629
Berger RP, Adelson PD, Pierce MC, Dulani T, Cassidy LD, Kochanek PM (2005) Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children. J Neurosurg 103:61–68
Dash PKZJ, Hergenroeder G, Moore AN (2010) Biomarkers for the diagnosis, prognosis and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 7(1):100–114
Schmid KE, Tortella FC (2012) The diagnosis of traumatic brain injury on the battlefield. Front Neurol 3:90
Woodcock T, Morganti-Kossmann MC (2013) The role of markers of inflammation in traumatic brain injury. Front Neurol 4:18
Arand M, Melzner H, Kinzl L, Bruckner UB, Gebhard F (2001) Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbecks Arch Surg 386:241–248
Arvin B, Neville LF, Barone FC, Feuerstein GZ (1996) The role of inflammation and cytokines in brain injury. Neurosci Biobehav Rev 20:445–452
Kossmann T, Stahel PF, Lenzlinger PM, Redl H, Dubs RW, Trentz O, Schlag G, Morganti-Kossmann MC (1997) Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production. J Cereb Blood Flow Metab 17:280–289
Kossmann T, Hans VH, Imhof HG, Stocker R, Grob P, Trentz O, Morganti-Kossmann C (1995) Intrathecal and serum interleukin-6 and the acute-phase response in patients with severe traumatic brain injuries. Shock 4:311–317
Johnson VE, Stewart JE, Begbie FD, Trojanowski JQ, Smith DH, Stewart W (2013) Inflammation and white matter degeneration persist for years after a single traumatic brain injury. Brain 136:28–42
Giulian D, Lachman LB (1985) Interleukin-1 stimulation of astroglial proliferation after brain injury. Science 228:497–499
Kossmann T, Hans V, Imhof HG, Trentz O, Morganti-Kossmann MC (1996) Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes. Brain Res 713:143–152
Tasci A, Okay O, Gezici AR, Ergun R, Ergungor F (2003) Prognostic value of interleukin-1 beta levels after acute brain injury. Neurol Res 25:871–874
Hergenroeder GW, Redell JB, Moore AN, Dash PK (2008) Biomarkers in the clinical diagnosis and management of traumatic brain injury. Mol Diagn Ther 12:345–358
Jeter CB, Hergenroeder GW, Hylin MJ, Redell JB, Moore AN, Dash PK (2013) Biomarkers for the diagnosis and prognosis of mild traumatic brain injury/concussion. J Neurotrauma 30(8):657–670
Gopcevic A, Mazul-Sunko B, Marout J, Sekulic A, Antoljak N, Siranovic M, Ivanec Z, Margaritoni M, Bekavac-Beslin M, Zarkovic N (2007) Plasma interleukin-8 as a potential predictor of mortality in adult patients with severe traumatic brain injury. Tohoku J Exp Med 211:387–393
Mussack T, Biberthaler P, Kanz KG, Wiedemann E, Gippner-Steppert C, Mutschler W, Jochum M (2002) Serum S-100B and interleukin-8 as predictive markers for comparative neurologic outcome analysis of patients after cardiac arrest and severe traumatic brain injury. Crit Care Med 30:2669–2674
Kumar RG, Rubin JE, Berger RP, Kochanek PM, Wagner AK (2016) Principal components derived from CSF inflammatory profiles predict outcome in survivors after severe traumatic brain injury. Brain Behav Immun 53:183–193
Csuka E, Morganti-Kossmann MC, Lenzlinger PM, Joller H, Trentz O, Kossmann T (1999) IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J Neuroimmunol 101:211–221
Knoblach SM, Faden AI (1998) Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp Neurol 153:143–151
Brenner T, Yamin A, Abramsky O, Gallily R (1993) Stimulation of tumor necrosis factor-alpha production by mycoplasmas and inhibition by dexamethasone in cultured astrocytes. Brain Res 608:273–279
Sawada M, Kondo N, Suzumura A, Marunouchi T (1989) Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res 491:394–397
Mier JW, Vachino G, van der Meer JW, Numerof RP, Adams S, Cannon JG, Bernheim HA, Atkins MB, Parkinson DR, Dinarello CA (1988) Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8:426–436
Shohami E, Gallily R, Mechoulam R, Bass R, Ben-Hur T (1997) Cytokine production in the brain following closed head injury: dexanabinol (HU-211) is a novel TNF-alpha inhibitor and an effective neuroprotectant. J Neuroimmunol 72:169–177
Goodman JC, Robertson CS, Grossman RG, Narayan RK (1990) Elevation of tumor necrosis factor in head injury. J Neuroimmunol 30:213–217
Ross SA, Halliday MI, Campbell GC, Byrnes DP, Rowlands BJ (1994) The presence of tumour necrosis factor in CSF and plasma after severe head injury. Br J Neurosurg 8:419–425
Stein DM, Kufera JA, Lindell A, Murdock KR, Menaker J, Bochicchio GV, Aarabi B, Scalea TM (2011) Association of CSF biomarkers and secondary insults following severe traumatic brain injury. Neurocrit Care 14:200–207
Stein DM, Lindell A, Murdock KR, Kufera JA, Menaker J, Keledjian K, Bochicchio GV, Aarabi B, Scalea TM (2011) Relationship of serum and cerebrospinal fluid biomarkers with intracranial hypertension and cerebral hypoperfusion after severe traumatic brain injury. J Trauma 70:1096–1103
Crespo AR, Da Rocha AB, Jotz GP, Schneider RF, Grivicich I, Pinheiro K, Zanoni C, Regner A (2007) Increased serum sFas and TNFalpha following isolated severe head injury in males. Brain Inj 21:441–447
Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:562–573
Higashida T, Kreipke CW, Rafols JA, Peng C, Schafer S, Schafer P, Ding JY, Dornbos D 3rd, Li X, Guthikonda M, Rossi NF, Ding Y (2011) The role of hypoxia-inducible factor-1alpha, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury. J Neurosurg 114:92–101
Wang X, Jung J, Asahi M, Chwang W, Russo L, Moskowitz MA, Dixon CE, Fini ME, Lo EH (2000) Effects of matrix metalloproteinase-9 gene knock-out on morphological and motor outcomes after traumatic brain injury. J Neurosci 20:7037–7042
Guilfoyle MR, Carpenter KL, Helmy A, Pickard JD, Menon DK, Hutchinson PJ (2015) Matrix metalloproteinase expression in contusional traumatic brain injury: a paired microdialysis study. J Neurotrauma 32:1553–1559
Liu CL, Chen CC, Lee HC, Cho DY (2014) Matrix metalloproteinase-9 in the ventricular cerebrospinal fluid correlated with the prognosis of traumatic brain injury. Turk Neurosurg 24:363–368
Roberts DJ, Jenne CN, Leger C, Kramer AH, Gallagher CN, Todd S, Parney IF, Doig CJ, Yong VW, Kubes P, Zygun DA (2013) Association between the cerebral inflammatory and matrix metalloproteinase responses after severe traumatic brain injury in humans. J Neurotrauma 30:1727–1736
Roberts DJ, Jenne CN, Leger C, Kramer AH, Gallagher CN, Todd S, Parney IF, Doig CJ, Yong VW, Kubes P, Zygun DA (2013) A prospective evaluation of the temporal matrix metalloproteinase response after severe traumatic brain injury in humans. J Neurotrauma 30:1717–1726
Grossetete M, Phelps J, Arko L, Yonas H, Rosenberg GA (2009) Elevation of matrix metalloproteinases 3 and 9 in cerebrospinal fluid and blood in patients with severe traumatic brain injury. Neurosurgery 65:702–708
Yang Y, Rosenberg GA (2011) Blood-brain barrier breakdown in acute and chronic cerebrovascular disease. Stroke 42:3323–3328
Zhiyuan Q, Qingyong L, Shengming H, Hui M (2016) Protective effect of rhEPO on tight junctions of cerebral microvascular endothelial cells early following traumatic brain injury in rats. Brain Inj 30:462–467
Cummins PM (2012) Occludin: one protein, many forms. Mol Cell Biol 32:242–250
Saitou M, Ando-Akatsuka Y, Itoh M, Furuse M, Inazawa J, Fujimoto K, Tsukita S (1997) Mammalian occludin in epithelial cells: its expression and subcellular distribution. Eur J Cell Biol 73:222–231
Shan R, Szmydynger-Chodobska J, Warren OU, Mohammad F, Zink BJ, Chodobski A (2016) A new panel of blood biomarkers for the diagnosis of mild traumatic brain injury/concussion in adults. J Neurotrauma 33:49–57
Verweij BH, Muizelaar JP, Vinas FC, Peterson PL, Xiong Y, Lee CP (2000) Impaired cerebral mitochondrial function after traumatic brain injury in humans. J Neurosurg 93:815–820
Sullivan PG, Keller JN, Bussen WL, Scheff SW (2002) Cytochrome c release and caspase activation after traumatic brain injury. Brain Res 949:88–96
Darwish RS, Amiridze NS (2010) Detectable levels of cytochrome C and activated caspase-9 in cerebrospinal fluid after human traumatic brain injury. Neurocrit Care 12:337–341
Lai Y, Stange C, Wisniewski SR, Adelson PD, Janesko-Feldman KL, Brown DS, Kochanek PM, Clark RS (2006) Mitochondrial heat shock protein 60 is increased in cerebrospinal fluid following pediatric traumatic brain injury. Dev Neurosci 28:336–341
Corcoran TB, Mas E, Barden AE, Durand T, Galano JM, Roberts LJ, Phillips M, Ho KM, Mori TA (2011) Are isofurans and neuroprostanes increased after subarachnoid hemorrhage and traumatic brain injury? Antioxid Redox Signal 15:2663–2667
Wang HC, Lin YJ, Shih FY, Chang HW, Su YJ, Cheng BC, Su CM, Tsai NW, Chang YT, Kwan AL, Lu CH (2016) The role of serial oxidative stress levels in acute traumatic brain injury and as predictors of outcome. World Neurosurg 87:463–470
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Azar, S. et al. (2017). Biofluid Proteomics and Biomarkers in Traumatic Brain Injury. In: Kobeissy, F., Stevens, Jr., S. (eds) Neuroproteomics. Methods in Molecular Biology, vol 1598. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-6952-4_3
Download citation
DOI: https://doi.org/10.1007/978-1-4939-6952-4_3
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-6950-0
Online ISBN: 978-1-4939-6952-4
eBook Packages: Springer Protocols